Plain-English translation of NCT06329401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pulmonary Fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a 52-week study testing whether pirfenidone solution for inhalation can safely slow the progression of lung scarring in people with progressive pulmonary fibrosis. Participants will be randomly assigned to receive either the medication at a high dose, the medication at a low dose, or a placebo (a dummy treatment with no active ingredient), all given by inhaling twice daily. The study will compare how well the medication works compared to placebo, alongside the medicines you may already be taking.
Progressive pulmonary fibrosis is a serious condition where lung tissue becomes increasingly scarred, making it harder to breathe over time. Currently available treatments help some patients, but doctors need to find better ways to slow or stop this progression. This medication has shown promise in earlier studies, and this trial will test whether inhaling it directly into the lungs is a safe and effective way to help patients.
You will visit the study site multiple times over 52 weeks (about one year). At each visit, you will have breathing tests and may have blood work and imaging scans to monitor your lung health. You will use an inhaler twice daily to breathe in either the medication or placebo at home. The study team will regularly check how you are doing and watch for any side effects, and you will be asked about your symptoms and how you are feeling throughout the trial.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States